$AGRX The concerns here are that the FDA still has concerns about Twirla. The proof behind that statement is that the FDA has not yet accepted the Adcom recommendation. If the FDA was ok with the Adcom recommendation you wouldn't have seen a delay issued. The FDA is still trying to decide. Don't forget how harsh the FDA was with their list of concerns prior to adcom. The bigger issue here is that if the FDA does not approve, Agile has NOTHING else to save the company. It's all riding on the Twirla approval. I am not saying this won't be approved, but understand that there are major concerns here. So don't go crazy.